Late-breaking observational data show patients with type 2 diabetes taking JANUVIA® (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin
(GCI Health NY) Merck, known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA® (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news
More News: Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Health | Insulin | International Medicine & Public Health | Janumet | Januvia | Merck | Metformin | Study